Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15121 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Robert Ritzel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Angiology, München Klinik Schwabing, Munich, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To compare the efficacy and safety of insulin glargine‐300 once daily (Gla‐300) with insulin degludec/aspart (IDegAsp) once daily in patients with type 2 diabetes (T2D) inadequately controlled on oral anti‐diabetic drugs (OADs). Materials and methods A systematic literature review of randomized controlled trials was followed by an indirect treatment comparison of studies involving insulin naïve adults, inadequately controlled [glycated haemoglobin (HbA1c) ≥7.0%] on OADs, who received Gla‐300 or IDegAsp once daily. Outcomes of interest were change in HbA1c, blood glucose, weight and insulin dose, as well as incidence and event rate of hypoglycaemia and other adverse events.
Results
Four trials with broadly similar baseline patient characteristics were included in the meta‐analyses and indirect treatment comparison. At 24‐28 weeks, the indirect comparison of Gla‐300 to IDegAsp once daily estimated no statistically significant difference for change in HbA1c (%) from baseline [mean difference of 0.10% (95% CI: −0.20, 0.39; p = .52)]; a statistically significant mean difference of −1.31 kg (95% CI: −1.97, −0.65; p < .05) for change in body weight from baseline; statistically significant odds ratios of 0.62 (95% CI: 0.41, 0.93; p < .05) for incidence of any hypoglycaemia; and 0.47 (95% CI: 0.25, 0.87; p < .05) for incidence of anytime confirmed hypoglycaemia (plasma glucose
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Angiology, München Klinik Schwabing, Munich, Germany.
- Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
- Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Ankara University, Ankara, Turkey.
- Department of Internal Medicine, Setif University Hospital, Sétif, Algeria.
- Department of Endocrinology and Metabolism, The Third Affiliated Hospital-Sun Yat-sen University, Guangzhou, China.
- Sanofi, Global Medical, Singapore, Singapore.
ORCID-Profile: Sujoy Ghosh, Rifat Emral, Wolfgang Landgraf, Divya Pushkarna, Rayaz A Malik
Förderung
- Sanofi
Zitieren
APA
Ritzel, R., Ghosh, S., Emral, R., Malek, R., Zeng, L., Mabunay, M. A., Landgraf, W., Guyot, P., Serafini, P., Pushkarna, D., & Malik, R. A. (2023). Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15121
Vancouver
Ritzel R, Ghosh S, Emral R, Malek R, Zeng L, Mabunay MA, et al. Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15121
BibTeX
@article{Ritzel2023,
author = {Ritzel, Robert and Ghosh, Sujoy and Emral, Rifat and Malek, Rachid and Zeng, Longyi and Mabunay, Maria Aileen and Landgraf, Wolfgang and Guyot, Patricia and Serafini, Paul and Pushkarna, Divya and Malik, Rayaz A},
title = {Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15121}
}
EUVIMED